Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ANNX
ANNEXON, INC.
NASDAQ
$4.87
▲ UP 0.62% (0.03)

KEY STATISTICS

Market Cap$792.16 M
52w High$7.18
52w Low$2.10
Dividend Yield—
Frequency—
P/E-3.99
Volume1.23M
Shares Out.163.84M

COMPANY

LEADERSHIP

Douglas E. Love
CHIEF EXECUTIVE
Douglas E. Love

COMPENSATION 2026

Salary$670,833
Stock Awards$0
Incentive Plan Pay$371,250
All Other Comp.$14,858
Total$3,579,202

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 24, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
92

PRICE TARGET

Target High$14.00
Target Low$7.00
Target Median$10.50
Target Consensus$10.50

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$3.50M
NOV
9
MON

PRICE

$4.87 ▲ UP 0.62% (+$0.03)
$4.80$4.83$4.85$4.889:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM4.87

About Annexon, Inc.

https://www.annexonbio.com ↗

Annexon, Inc. is a clinical-stage biopharmaceutical company developing therapies targeting autoimmune, neurodegenerative, and ophthalmic disorders, with candidates like ANX005 and ANX009 in various clinical trial phases.

INDUSTRY

Biotechnology

A PRODUCT ANNEXON, INC. IS KNOWN FOR

ANX005
ANX005

ANX005 is an investigational monoclonal antibody by Annexon, in late-stage development, targeting C1q to treat neuroinflammatory and autoimmune diseases, with positive Phase 3 results for Guillain-Barré Syndrome.

COMPETITORS

COMPETITOR
ALNY COMPARE
QTTB COMPARE
REGN COMPARE
RLYB COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
127
LISTED HERE
19
RANKED BY POSITION SIZE
XBI
0.28% · 6.6M
VTS.AX
0.00% · 5.0M
XSU.TO
0.02% · 4.0M
FESM
0.07% · 891.1K
SCHA
0.02% · 718.5K
DFAS
0.01% · 326.1K
LABU
0.19% · 221.8K
PRFZ
0.04% · 210.3K
XRS2.DE
0.02% · 138.7K
RSSL
0.02% · 74.5K
BBC
0.63% · 66.6K
GSSC
0.02% · 42.4K
RTWP.L
0.03% · 14.7K
RFLR
0.04% · 8.1K
URTY
0.01% · 6.1K
VETS
0.06% · 3.1K
PQ
PQSG
0.19% · 1.2K
USFMDN.MX
0.00% · 555
RESM
0.02% · 279

INSTITUTIONAL OWNERSHIP

SHARES OWNED
57.98%
HOLDERS
250
TOP 12 OF 250 · RANKED BY POSITION SIZE
Redmile Group, LLC
14.5M sh · $80.61M
Fmr LLC
11.1M sh · $33.8M
Blackrock, Inc.
10.9M sh · $60.6M
Bvf Inc/Il
9.1M sh · $45.82M
Vanguard Group Inc
7.8M sh · $38.92M
Alerce Investment Management, L.P.
7.4M sh · $37.99M
State Street Corp
6.9M sh · $38.33M
Blackrock Inc.
6.6M sh · $32.28M
Adage Capital Partners Gp, L.L.C.
5.5M sh · $27.61M
Bain Capital Life Sciences Investors, LLC
5.2M sh · $26.35M
Bellevue Group AG
5.2M sh · $28.57M
Mak Capital One LLC
4.7M sh · $26.17M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
Blumenkranz Mark S.
— · —
2026-08-10
★
DIRECTOR
Blumenkranz Mark S.
Purchase · 175.0K shares
2026-08-10
★
DIRECTOR
Cockroft Bettina M.
Purchase · 65.0K shares
2026-06-11
★
DIRECTOR
Choi Jung
Purchase · 65.0K shares
2026-06-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 2
BUY 2
MARKET PERFORM 1
5 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Citizens MARKET PERFORM Needham BUY Chardan Capital BUY Wells Fargo OVERWEIGHT

SECTORS PEERS

PEERPRICE
LBRX$49.74COMPARE
AURA$7.54COMPARE
ALT$3.37COMPARE
KYTX$8.34COMPARE
LRMR$3.84COMPARE
DMAC$6.79COMPARE
DBVT$13.56COMPARE
ACIU$2.85COMPARE